Gabapentin Capsule
Product Images NDC 58118-3224

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 58118-3224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 400mg Capsules 30ct Blister Card (Gabapentin 100mg 100cap)

Gabapentin 400 mg capsule packaging label from Clinical Solutions Wholesale, LLC. The label includes the product name, strength, dosage form, and NDC 58118-3224-8. It specifies a quantity of 30 capsules and lists Ascend Laboratories, LLC in Parsippany, NJ, as the manufacturer. Additional details include lot number SAMPLE123, batch number SAMPLE456, and expiration date January 2026.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula for calculating creatinine clearance (CLCr) based on patient age, weight, and serum creatinine levels, with an adjustment factor for female patients. This text is likely part of dosing or renal function guidance related to Gabapentin capsules 400 mg.*

FDA Label Image

Structure (Gabapentin Fig 5)

Chemical structure of gabapentin, showing a cyclohexane ring with attached amine (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph comparing mean pain scores over 8 weeks between a placebo group and a Gabapentin 3600 mg/day group. The x-axis shows time in weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period and a 4-week fixed dose period.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph depicting mean pain scores over 7 weeks, comparing placebo with Gabapentin at daily doses of 1800 mg and 2400 mg. The timeline is divided into a 3-week dose titration period followed by a 4-week fixed dose period, showing changes in pain scores from baseline through week 7.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at different doses. Study 1 shows 12% responders for PBO and 29% for GBP 3600. Study 2 shows 14% for PBO, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance markers are noted for p < 0.01 and p < 0.001.*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

A scatter plot chart presenting the relationship between daily dose (mg) of gabapentin and percentage difference. The x-axis shows daily dose values of 600, 900, 1200, and 1800 mg, while the y-axis displays percentage differences ranging from 2% to 22%. The chart compares results from three studies labeled as Study a (black squares), Study b (gray squares), and Study c (white squares), with data points annotated with letters a, b, and c at various doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.